Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nalmefene for Impulse Control Disorders in Parkinson's Disease
NCT02934919Phase 2Unknown
- Sponsor
- Centre Hospitalier Universitaire de Clermont-Ferrand
- Start
- Dec 2016
- Primary completion
- Mar 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nalmefene in impulse control disorder (ICD), sponsored by Centre Hospitalier Universitaire de Clermont-Ferrand. Primary endpoints: Dropout rate secondary to adverse effects at 3 months and Questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease - Rating Scale at 3 months. Status: unknown.
02
Drugs
nalmefene
03
Conditions
impulse control disorder (ICD)
Beyond the preview
Go deeper on NCT02934919.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02934919.